---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（200952603290421.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文依非韦伦处方资料（仅供参考）

英文药名: Sustiva (efavirenz)

中文药名: 依非韦伦, 依法韦恩茨

药品名称
【药物名称】依法韦仑（英文：Efavirenz），依法韦恩茨 Efavirenz

药理毒理
依法韦恩茨(efavirenz)是1998年9月FDA批准在美国上市的非核苷逆转录酶抑制剂(NNRTI)，是治疗人类免疫缺陷病毒1型(HIV-1)的特效药，商品名为SUSTIVA。由于单用一种NNRTI时能很快产生耐药病毒，因此本品通常与其它的抗逆转录酶病毒药物联合应用。本品是人类免疫缺陷病毒1型(HIV-1)的NNRTI，主要作用是非竞争性地抑制HIV-1的逆转录酶，而对HIV-2逆转录酶和人体细胞DNA的α，β，γ，δ多聚酶没有抑制作用。

适应症
本品应与其它的抗逆转录酶病毒药物联合使用，治疗HIV-1感染。

用法用量　
成人：建议剂量600mg，每日一次，口服。与蛋白酶抑制剂或/和核苷逆转录酶抑制剂合用。 　　
儿童：年龄在3岁以上，体重10～40kg者，建议本品剂量为200～400mg；体重高于40kg者，建议剂量600mg，每日一次，口服。 　　
本品可以与食物同服，但高脂肪的食物可增加本品的吸收，应避免。
为了增加患者对神经系统不良反应的耐受性，开始治疗的2～4周或已经出现不良反应症状且继续用药的患者，建议在临就寝前服用。
任何疑问，请遵医嘱！

不良反应
本品最重要的不良反应是神经系统症状和皮疹。 　　
神经系统症状：眩晕、嗜睡、失眠、多梦、思维异常、注意力分散、记忆力减退、焦虑、幻觉、欣快等.　皮疹.　　
偶见的其它不良反应有：口干、耳鸣、复视、嗅觉味觉异常、面色潮红、心悸、心动过速、血栓性静脉炎、关节痛、哮喘、脱发、转氨酶升高、肝炎、胆固醇升高等。

药物相互作用
本品不应同时与阿司咪唑、西沙必利、咪达唑仑、三唑仑或麦角碱衍生物合用，因为本品可抑制这些药物代谢而存在严重的、或危及生命的不良反应。

注意事项　
禁用于对本品的任何成分过敏者。　
单用一种NNRITs治疗HIV时，病毒能很快产生耐药，因此本品不应作为单一药物治疗HIV或单位使用于治疗失败的病例。应与至少一种患者从未应用过的其它抗逆转录酶病毒药物联合应用。

规格
胶囊剂：90粒/瓶，200mg/粒；
30粒/瓶，50mg,100mg,200mg或600mg/粒。

IMPORTANT INFORMATION ABOUT SUSTIVA® (efavirenz)
INDICATION:
SUSTIVA® (efavirenz) is a prescription medicine used in combination with other medicines to treat people who are infected with the human immunodeficiency virus type 1 (HIV-1).

SUSTIVA does not cure HIV and has not been shown to prevent passing HIV to others.

See your healthcare provider regularly.

IMPORTANT SAFETY INFORMATION:
Do not take SUSTIVA if you are taking the following medicines because serious and life-threatening side effects may occur when taken together: Vascor® (bepridil),
Propulsid® (cisapride),
Versed® (midazolam), Orap® (pimozide), Halcion® (triazolam), or ergot medicines (for example,Wigraine® and Cafergot®).

Taking SUSTIVA with St. John’s wort (Hypericum perforatum) is not recommended, as it may cause decreased levels of SUSTIVA, increased viral load, and possible resistance to SUSTIVA or cross-resistance to other anti-HIV drugs.

SUSTIVA should not be taken with ATRIPLA® (efavirenz 600 mg / emtricitabine 200 mg/tenofovir    disoproxil fumarate 300mg) because it contains efavirenz, the active ingredient in SUSTIVA.

If you are taking SUSTIVA with
REYATAZ® (atazanavir sulfate), your REYATAZ may need to be replaced if this is not the first time you are receiving treatment for your HIV infection. Other drugs that may also need to be replaced include
Fortovase® (saquinavir),
Invirase® (saquinavir),
Biaxin® (clarithromycin),
Carbatrol® (carbamazepine),
Tegretol® (carbamazepine),
Noxafil® (posaconazole) and
Sporonox® (itraconazole).

SUSTIVA and Vfend® (voriconazole)
must not be taken together at standard doses. Some doses of voriconazole can be taken at the same time as a lower dose of SUSTIVA, but you must check with your healthcare provider first.

These are not all the medicines that may cause problems if you take SUSTIVA® (efavirenz). Discuss with your healthcare provider all prescription and nonprescription medicines, vitamins, and herbal supplements you are taking or plan to take.

Tell your healthcare provider right away if you have any side effects or conditions, including the following:
•Severe depression, strange thoughts, or angry behavior have been reported by a small number of patients taking SUSTIVA. Some patients have had thoughts of suicide and a few have actually committed suicide. These problems may occur more often in patients who have had mental illness.
•Dizziness, trouble sleeping or concentrating, drowsiness, and/or unusual dreams, are
common, and tend to go away after taking SUSTIVA for a few weeks. Symptoms were severe in a few patients, and some patients discontinued therapy. These symptoms may become more severe with the use of alcohol and/or mood-altering (street) drugs. If you are dizzy, have trouble concentrating, and/or are drowsy, avoid activities that may be dangerous, such as driving or operating machinery.
•If you have ever had mental illness or are using drugs or alcohol.
•Pregnancy: Women should not become pregnant while taking SUSTIVA® (efavirenz) and for 12 weeks after stopping SUSTIVA. Serious birth defects have been seen in children of women treated with SUSTIVA during pregnancy. Therefore, women must use a reliable form of barrier contraception, such as a condom or diaphragm, even if they also use other methods of birth control.
•Breast-feeding: Women with HIV should not breast-feed because they can pass HIV through their milk to the baby. Also, SUSTIVA may pass through breast milk and cause serious harm to the baby.
•Rash is a common side effect that usually goes away without any change in your medicines, but may be serious in a small number of patients. Rash may be a serious problem in some children.
•Liver problems: Some patients taking SUSTIVA have experienced serious liver problems including liver failure resulting in transplantation or death. Most of these serious side effects occurred in patients with a chronic liver disease such as hepatitis infection, but there have also been reports in patients without any existing liver disease. Your healthcare provider may want to do tests to check your liver.
•Seizures have occurred in patients taking SUSTIVA, usually in those with a history of seizures. If you have ever had seizures or take medicines for seizures, your healthcare provider may want to switch you to another medicine or monitor you.

Changes in body fat have been seen in some patients taking anti-HIV medicines. The cause and long-term health effects are not known.

Other common side effects of SUSTIVA® (efavirenz) taken with other anti-HIV medicines include: tiredness, upset stomach, vomiting, and diarrhea. Some patients taking SUSTIVA have experienced increased levels of lipids (cholesterol and triglycerides) in the blood.

You should take SUSTIVA on
an empty stomach, preferably at bedtime, which may make some side effects less bothersome.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件（200952603290421.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------